These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 8452572

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors.
    Rainsford KD, Ying C, Smith F.
    J Pharm Pharmacol; 1996 Jan; 48(1):46-52. PubMed ID: 8722494
    [Abstract] [Full Text] [Related]

  • 23. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM, Spruce KE, Crawley GC, Walker ER, Foster SJ.
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Conformational analysis of 5-lipoxygenase inhibitors: role of the substituents in chiral recognition and on the active conformations of the (methoxyalkyl)thiazole and methoxytetrahydropyran series.
    Lambert-van der Brempt C, Bruneau P, Lamorlette MA, Foster SJ.
    J Med Chem; 1994 Jan 07; 37(1):113-24. PubMed ID: 8289184
    [Abstract] [Full Text] [Related]

  • 27. Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization.
    Falgueyret JP, Denis D, Macdonald D, Hutchinson JH, Riendeau D.
    Biochemistry; 1995 Oct 17; 34(41):13603-11. PubMed ID: 7577949
    [Abstract] [Full Text] [Related]

  • 28. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.
    Stock N, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):213-7. PubMed ID: 19914828
    [Abstract] [Full Text] [Related]

  • 29. Sensitivity of immunoaffinity-purified porcine 5-lipoxygenase to inhibitors and activating lipid hydroperoxides.
    Riendeau D, Falgueyret JP, Nathaniel DJ, Rokach J, Ueda N, Yamamoto S.
    Biochem Pharmacol; 1989 Jul 15; 38(14):2313-21. PubMed ID: 2502118
    [Abstract] [Full Text] [Related]

  • 30. N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase.
    Connolly PJ, Wetter SK, Beers KN, Hamel SC, Chen RH, Wachter MP, Ansell J, Singer MM, Steber M, Ritchie DM, Argentieri DC.
    Bioorg Med Chem Lett; 1999 Apr 05; 9(7):979-84. PubMed ID: 10230624
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of tumour growth by lipoxygenase inhibitors.
    Hussey HJ, Tisdale MJ.
    Br J Cancer; 1996 Sep 05; 74(5):683-7. PubMed ID: 8795568
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. 5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643)-A potent FLAP inhibitor suitable for topical administration.
    Stock N, Baccei C, Bain G, Chapman C, Correa L, Darlington J, King C, Lee C, Lorrain DS, Prodanovich P, Santini A, Schaab K, Evans JF, Hutchinson JH, Prasit P.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4598-601. PubMed ID: 20566292
    [Abstract] [Full Text] [Related]

  • 36. Investigation of the mechanism of non-turnover-dependent inactivation of purified human 5-lipoxygenase. Inactivation by H2O2 and inhibition by metal ions.
    Percival MD, Denis D, Riendeau D, Gresser MJ.
    Eur J Biochem; 1992 Nov 15; 210(1):109-17. PubMed ID: 1446663
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors.
    Fischer L, Szellas D, Rådmark O, Steinhilber D, Werz O.
    FASEB J; 2003 May 15; 17(8):949-51. PubMed ID: 12670876
    [Abstract] [Full Text] [Related]

  • 40. Evidence that endogenous generation of leukotrienes does not regulate proliferation of malignant hemopoietic cell lines.
    Ayyub Khan M, Tateson JE, Hoffbrand AV, Wickremasinghe RG.
    Leuk Res; 1993 Mar 15; 17(3):241-5. PubMed ID: 8450672
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.